Rates of ERBB2 Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-amplified Acral Melanoma.
Melanoma Literature
Publication date: Aug 09, 2018 Patients with BRAF V600-wild type melanoma whose tumors progress on checkpoint inhibition currently have limited therapeutic options, and additional rational treatment targets are needed. ERBB2 ... Read more